• 1
    Ganz PA. Impact of quality of life outcomes on clinical practice. Oncology (Williston Park). 1995; 9( 11 suppl): 61-65.
  • 2
    Lipscomb J, Reeve BB, Clauser SB, et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol. 2007; 25: 5133-5140.
  • 3
    Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295: 2742-2751.
  • 4
    Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades Ann Oncol. 2002; 13: 197-207.
  • 5
    Karamouzis MV, Ioannidis G, Rigatos G. Quality of life in metastatic breast cancer patients under chemotherapy or supportive care: a single-institution comparative study. Eur J Cancer Care (Engl). 2007; 16: 433-438.
  • 6
    Bottomley A, Biganzoli L, Cufer T, et al. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. J Clin Oncol. 2004; 22: 2576-2586.
  • 7
    Carlson LE, Koski T, Gluck S. Longitudinal effects of high-dose chemotherapy and autologous stem cell transplantation on quality of life in the treatment of metastatic breast cancer. Bone Marrow Transplant. 2001; 27: 989-998.
  • 8
    Efficace F, Biganzoli L, Piccart M, et al. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer. 2004; 40: 1021-1030.
  • 9
    Modi S, Panageas KS, Duck ET, et al. Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol. 2002; 20: 3665-3673.
  • 10
    Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997; 15: 974-986.
  • 11
    Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics. 1989; 45: 781-795.
  • 12
    Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986; 4: 1772-1779.
  • 13
    Glasziou PP, Cole BF, Gelber RD, Hilden J, Simes RJ. Quality adjusted survival analysis with repeated quality of life measures. Stat Med. 1998; 17: 1215-1229.
  • 14
    Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001; 358: 277-286.
  • 15
    Gelber RD, Cole BF, Gelber S, Goldhirsch A. Comparing treatments using quality-adjusted survival: The Q-TWiST method. Am Stat. 1995; 49: 161-169.
  • 16
    Sherrill B, Amonkar MM, Stein S, Walker M, Geyer C, Cameron D. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer. 2008; 99: 711-715.
  • 17
    [no authors listed]. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998; 352: 930-942.
  • 18
    Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007; 25: 5210-5217.
  • 19
    Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010; 28: 3256-3263.
  • 20
    Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005; 90: 295-298.
  • 21
    Wei L, Lachin J. Two-sample asymptotically distribution free tests for incomplete multivariate observations. J Am Stat Assoc. 1984; 79: 653-661.
  • 22
    Diehr P, Patrick DL, McDonell MB, Fihn SD. Accounting for deaths in longitudinal studies using the SF-36: the performance of the Physical Component Scale of the Short Form 36-item health survey and the PCTD. Med Care. 2003; 41: 1065-1073.
  • 23
    Diehr P, Patrick DL, Spertus J, Kiefe CI, McDonell M, Fihn SD. Transforming self-rated health and the SF-36 scales to include death and improve interpretability. Med Care. 2001; 39: 670-680.
  • 24
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 25
    Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990; 9: 1259-1276.
  • 26
    Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000; 18: 3302-3317.
  • 27
    Reed SD, Li Y, Anstrom KJ, Schulman KA. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2009; 27: 2185-2191.
  • 28
    Revicki DA, Feeny D, Hunt TL, Cole BF. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res. 2006; 15: 411-423.
  • 29
    Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002; 20: 1311-1318.